Atrial Fibrillation
Cardiovascular 2 original drugsCardiovascular indication. Atrial Fibrillation has 2 FDA-approved novel treatments, led by DAIICHI SANKYO INC, with 138 active industry clinical trials across 15 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Atrial Fibrillation Market Leaders
Companies with the most FDA-approved novel Atrial Fibrillation drugs.
Phase 3 Readouts Pro
1 active Phase 3 trial with confidence-graded completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Atrial Fibrillation Treatments by Mechanism
Top 3 mechanisms across 6 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Atrial Fibrillation Clinical Pipeline by Phase
129 industry-sponsored trials across 55 sponsors
Novel Atrial Fibrillation Drugs by Company (New molecular entities)
2 companies have an FDA-approved novel drug for Atrial Fibrillation.
Reformulations (21 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Atrial Fibrillation Drug Targets
Molecular targets of approved and investigational Atrial Fibrillation drugs — 15 targets tracked.
Generic Drugs (11 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs